newsfilter
← Latest News
GlobeNewswire·

Q32 Bio and Homology Medicines Announce Merger Agreement

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia